Surrozen (NASDAQ:SRZN – Get Free Report) and Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.
Earnings and Valuation
This table compares Surrozen and Soleno Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Surrozen | $10.65 million | 19.70 | -$63.56 million | ($22.34) | -1.10 |
| Soleno Therapeutics | N/A | N/A | -$175.85 million | ($1.84) | -20.24 |
Profitability
This table compares Surrozen and Soleno Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Surrozen | -2,909.10% | -4,055.04% | -88.90% |
| Soleno Therapeutics | N/A | -25.88% | -19.84% |
Insider & Institutional Ownership
66.6% of Surrozen shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 45.2% of Surrozen shares are owned by insiders. Comparatively, 6.4% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
Surrozen has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -3.16, indicating that its share price is 416% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Surrozen and Soleno Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Surrozen | 1 | 0 | 1 | 1 | 2.67 |
| Soleno Therapeutics | 1 | 1 | 12 | 1 | 2.87 |
Surrozen currently has a consensus target price of $32.00, suggesting a potential upside of 30.72%. Soleno Therapeutics has a consensus target price of $110.62, suggesting a potential upside of 197.03%. Given Soleno Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than Surrozen.
Summary
Soleno Therapeutics beats Surrozen on 8 of the 13 factors compared between the two stocks.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
About Soleno Therapeutics
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
